The FDA has granted accelerated approval to Bristol Myers Squibb’s Zenbexus, the first FDA-approved cereblon E3 ligase modulator, or CELMoD, a new class of treatment for multiple myeloma.
Zenbexus (iberdomide), in combination with daratumumab and hyaluronidase-fihj and dexamethasone, was approved for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
The approval was based on the phase 3 Excaliber-Rrmm trial. After a median follow-up of 16 months, 41% of patients receiving the Zenbexus combination had no detectable signs of cancer remaining after treatment, compared with 21% of patients receiving daratumumab, bortezomib and dexamethasone.
Fatal adverse reactions occurred in 10 patients, or 4.9%, who received Zenbexus. The combination can cause serious, life-threatening or fatal infections and severe neutropenia. Zenbexus also carries boxed warnings for embryo-fetal toxicity and venous and arterial thromboembolism. Full approval for the indication is contingent on verification of clinical benefit in a confirmatory trial.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
